Concert Pharma (CNCE) Tops Q4 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Concert Pharma (CNCE) Announces Results from Part 1 of Ascending Dose Phase 1 of CTP-656; Prior PK Results Affirmed
February 29, 2016 4:08 PM ESTConcert Pharmaceuticals, Inc. (NASDAQ: CNCE) announced new results from Part 1 of its multiple ascending dose Phase 1 clinical trial in which a single-dose tablet formulation of CTP-656 was compared to the commercial tablet formulation of Kalydeco®, the current standard of care for cystic fibrosis patients with gating mutations. The results from this study confirmed CTP-656s... More
